KRAS and familial pancreatic carcinoma: Acquired therapy-resistance is a major concern nowadays, as it has been shown for KRAS-driven chemotherapy-resistant pancreatic cancers or KRASG12C-inhibitors in several KRAS-driven cancer types, for example [43,44].